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6 Versus 12 Months of
Dual Antiplatelet TherapyWith great interest, I read the article by Colombo et al.
(1) that examined the noninferiority of 6 versus 12
months of dual antiplatelet therapy (DAPT) in
patients undergoing percutaneous coronary inter-
vention with second-generation drug-eluting stents.
The investigators described in the Results section
(p. 2091) that “There was at least 1 occurrence of the
primary composite endpoint by 12 months in 31 pa-
tients in the 6-month DAPT group (4.5%; 95% CI: 2.9
to 6.1) and 27 patients in the 12-month DAPT group
(3.7%; 95% CI: 2.3 to 5.1; p ¼ 0.469) (Table 5). There
was a 0.8% (95% CI: -2.4 to 1.7) difference in occur-
rence of the primary endpoint between the 6-month
and 12-month groups. The upper limit of the 95% CI
was lower than the pre-set margin of 2%, conﬁrming
the noninferiority hypothesis (p < 0.05).” However,
on the basis of the result (31 of 682 vs. 27 of 717) in
Table 5, the 95% conﬁdence interval (CI) for the dif-
ference between 2 sample proportions is -1.3% to
2.9% (90% CI: -1.0 to 2.5). Therefore, the upper limit
of the 95% CI appears more than the pre-set margin of
2%, rejecting the noninferiority hypothesis of 6
months versus 12 months of DAPT. It would be of
great help if the investigators could provide the
method they used to calculate 95% CI.*Hideaki Kaneda, MD, PhD
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Establish NoninferiorityIn presenting the results of the SECURITY (Second-
Generation Drug-Eluting Stent Implantation Fol-
lowed by 6- Versus 12-Month Dual Antiplatelet
Therapy) trial, Colombo et al. (1) concluded that
“6 months of DAPT appeared noninferior to a
12-month regimen with respect to the primary com-
posite endpoint.” However, this conclusion, repeated
several times in the paper, is not supported by the
data.
The composite event was observed in 31 of 682
patients in the 6-month treatment arm, and in 27 of
717 patients in the 12-month arm. The risks were
correctly reported as 4.5% versus 3.7%, and the risk
difference as 0.8%. The 95% conﬁdence interval was
given as -2.4% to 1.7%, such that “the upper limit of
the 95% CI was lower than the pre-set margin of 2%,
conﬁrming the noninferiority hypothesis.” Unfortu-
nately, the conﬁdence bounds are incorrect. The
tell-tale sign of a problem is the asymmetry; the
conﬁdence interval should be approximately sym-
metric about the point estimate of 0.8%. Reanalysis
shows an asymptotic 95% conﬁdence interval of -1.3%
to 2.9%, which exceeds the noninferiority margin. If
an exact conﬁdence interval is preferred, which may
be a good idea given the low numbers of events, the
bounds are -1.7% to 3.9%. This means that the data
are compatible with an absolute excess risk of a
composite event of up to 2.9% (or 3.9%) in a patient
treated for 6 months, compared with a patient treated
for 12 months. Noninferiority up to an excess risk of
2% does not hold.
The problem remains if a 1-sided 95% conﬁdence
interval is obtained, as it should according to the
Methods section. A 1-sided upper limit on the risk
difference of 0.8% is 2.5% (asymptotic method) or
3.4% (exact method). In all instances, the upper limit
exceeds the noninferiority margin.
Another issue that argues against noninferiority is
the rather high proportion of patients (34%) in
the 6-month treatment group who continued their
medications beyond the scheduled stopping time.
Non-compliance with the assigned treatment dilutes
the contrast between the groups. This favors the null
hypothesis and causes a conservative bias in su-
periority trials: indeed, if a signiﬁcant difference is
observed between the treatment arms despite
noncompliance, the true difference must be even
greater. In contrast, in a noninferiority trial, the bias
caused by noncompliance runs against the tested
